Topical therapy for scalp: from traditions to innovations

Abstract

About 80% ofpsoriasis patients with involvement of glabrous skin develop also involvement of the hairy part of the head; however, in 25% of cases psoriasis of the hairy part of the head is an isolated condition. In almost 48% ofpatients psoriatic efflorescence involve the greater part of the head (hairy part, face, ears), and 82% ofpatients suffering from the dermatosis permanently suffer from discomfort and look unpleasant, which becomes a cause of deep social isolation and disadaptation. Modern algorithm of therapy for scalp psoriasis in accordance with the recommendations of the European Academy of Dermatology and Venereology (2009), includes short contact preparations in the form of shampoos. Etrivex shampoo is the first and the only short contact drug, developed for the treatment of scalp psoriasis. The main component of the shampoo is clobethasole propionate (0.05%), other components are cleaning and foamy agents, conditioners, etc., due to which the therapeutic efficiency of fourth-generation glucocorticoids is fully utilized in parallel with cosmetic care of the hair. Etrivex shampoo was effectively used in therapy of our 15 patients with psoriasis of the hairy part of the head.

Keywords

psoriasis / hairy part of the head / topical therapy / clobethasole propionate / Etrivex shampoo

References

[1] Ortonne J., Chimenti S., Luger T., Puig L., Reid F., Trueb R.M. Scalp psoriasis: European consensus on grading and treatment algorithm. J. Eur. Acad. Dermatol. Venereol. 2009; 23(12): 1435-44. doi: 10.1111/j.1468-3083.2009.03372.x.

[2] Bovenschen H.J., Van de Kerkhof P.C. Treatment of scalp psoriasis with clobeta-sol-17 propionate 0.05% shampoo, a study on daily clinical practice. J. Eur Acad. Dermatol. Venereol. 2010; 24(4): 439-44.

[3] Якубович И.А., Новицкая Н.Н. Псориаз и качество жизни. Иркутск: Риэл; 2011: 27-47. [Yakubovich I.A. Novitskaya N.N. Psoriasis and quality of life [Psoriaz i kachestvo zhizni]. Irkutsk: Real; 2011: 27^-7]. (in Russian)

[4] Horn E.J., Fox K.M., Patel V, Chiou C.F., Dann F., Lebwohl M. Association of patient-reported psoriasis severity with income and employment. J. Am. Acad. Dermatol 2007; 57(6): 963-71.

[5] National Psoriasis Foundation Benchmark Survey. 2006. Available at: http://www. psoriasis.org/files/pdfs/press/npfsurvey

[6] Krueger G., Koo J., Lebwohl M., Menter A., Stern R.S., Rolstad T. The impact of psoriasis on quality of life: results of a 1998 National Psoriasis Foundation patient-membership survey. Arch. Dermatol. 2001; 137(3): 280^.

[7] Fortune D.G., Richards H.L., Griffiths C.E. Psychologic factors in psoriasis: consequences, mechanisms, and interventions. Dermatol. Clin. 2005; 23(4): 681-94.

[8] Aubert J., Reiniche P., Fogel P., Poulin Y., Lui H., Lynde C., et al. Gene expression profiling in psoriatic scalp hair follicles: clobetasol propionate shampoo 0.05% normalizes psoriasis disease markers. J. Eur. Acad. Dermatol. Venereol. 2010; 24(11): 1304-11. doi: 10.1111/j.1468-3083.2010.03637.x.

[9] Бакулев А.Л., Кравченя С.С. Псориаз волосистой части головы: новые возможности топической терапии. Вестник дерматологии и венерологии. 2013; 2: 73-8. [Bakulev A.L., Kravchenja S.S. Psoriasis of the scalp: new opportunities topical therapy. Vestnik dermatologii i venerologii. 2013; 2: 73-8]. (in Russian)

[10] Papp K., Poulin Y., Barber K., Lynde C., Prinz J.C., Berg M., et al. Cost-effectiveness evaluation of clobetasol propionate shampoo (CPS) maintenance in patients with moderate scalp psoriasis: a Pan-European analysis. J. Eur. Acad. Dermatol. Venereol 2012; 26(11): 1407-14. doi: 10.1111/j.1468-3083.2011.04305.x.

RIGHTS & PERMISSIONS

Eco-Vector